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The Transplant Unit, Wits Donald Gordon Medical 
Centre, University of the Witwatersrand, Johannesburg, 
South Africa has performed 43 paediatric liver 
transplants to date. Of these, 8 were combined liver-
kidney transplants. Since the first successful kidney and 
liver transplants in the 1950s and 1960s respectively, both patient and 
graft survival have improved dramatically.[1] The first successful combined 
liver-kidney transplantation (CLKT) was subsequently performed by 
Margreiter in Austria in 1984.[2] Renal insufficiency, secondary to a 
variety of causes, is a common problem in patients suffering from end-
stage liver disease, particularly in adults.[3] Renal impairment in liver 
transplant patients amplifies the risk for both postoperative chronic 
kidney disease (CKD) and procedure-related mortality. With the 
introduction of the Model for End-Stage Liver Disease (MELD) score 
for liver transplantation the allocation of organs to patients with renal 
insufficiency has increased.[1-3] Consequently, the number of CLKTs 
in adults has shown a considerable increase over the last few years. In 
children, the most common causes for CLKT are congenital diseases 
affecting both liver and kidney, such as primary hyperoxaluria type 1 
(PH1) and autosomal recessive polycystic kidney disease (ARPKD). [2] 
These diseases have a low incidence and consequently CLKT in children 
remains a therapy performed in a very limited number of cases with little 
data available in the literature.[1] 
Methods
All paediatric patients undergoing CLKT were identified retrospectively. 
Eight transplants were performed in 8 children (<18 years of age on 
the day of transplant) since 2005. Recipient characteristics are listed in 
Table  1. Pertinent intra- and postoperative events were documented, 
as were any postoperative complications (particularly those related to 
vascular, biliary or urinary reconstruction) and graft and patient survival 
were analysed. Finally, a retrospective, English-language PubMed search 
was conducted in January 2013 for all published papers relating to CLKT.
Results
Eight CLKTs were performed, none of the children having received 
previous transplants. Indications included congenital hepatic fibrosis 
associated with polycystic kidney disease (PKD) (n=3), PH1 (n=4) 
and heterozygous factor H deficiency with atypical haemolytic 
uraemic syndrome (aHUS) (n=1). Patients ranged in age from 4 to 
17 years (median 9) and included 4 females and 4 males. Weight 
ranged from 13 to 42 kg (median 22.5). Waiting times on the active 
transplant list ranged from 49 to 1 383 days (median 270). The range 
of post-transplant follow-up was 6 - 65 months.
Graft combinations were as follows: whole liver and one kidney (n=5); 
whole liver and two kidneys (n=1) and left lateral segment of liver and 
one kidney (n=2). Median anaesthetic time was 7  hrs and blood loss 
ranged from 80 to 4  970  ml (median 1  831). Median blood volume 
transfused was 900 ml of leukocyte-depleted packed red blood cells and 
other blood products, and 450 ml of cell-saved whole blood. Blood group 
crossmatch was identical in 7 patients and compatible in 1 patient.
Induction immunosuppression consisted of daclizumab (Zenapax) 
(weight <40  kg: 10  mg intravenous injection (IVI) on days 1 and 4; 
weight >40  kg: 20  mg IVI on days 1 and 4) and methylprednisolone 
(Solu-Medrol) (600  mg/m2 to a maximum of 500  mg). Postoperative 
maintenance immunosuppression consisted of mycophenolate 
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mofetil (CellCept), tacrolimus (Prograf) 
and prednisone. In one case, everolimus was 
used after conversion from the calcineurin 
inhibitor. With respect to preoperative dialysis, 
6 patients received haemodialysis, 1 peritoneal 
dialysis, and 1 was transplanted pre-emptively. 
The child with aHUS received polyvalent 
human normal immunoglobulin (Polygam) 
and plasma exchange pre-transplant, as well as 
for 10 days post-transplant. Eculizumab was 
not used as it was not available in South Africa 
at the time. No patients required postoperative 
dialysis for delayed graft function. All patients 
with hyperoxaluria received 3 months of 
postoperative haemodialysis to decrease 
systemic oxalate load. This patient group 
presented pre-transplant with manifestations 
of systemic oxalosis, particularly dense 
nephrocalcinosis. One patient underwent 
sequential nephrectomies, the first pre- 
and the second post-CLKT, both for severe 
nephrocalcinosis and recurrent urinary tract 
infections. A second patient is currently being 
considered for bilateral nephrectomy for the 
same reason. Native kidneys in the remaining 
patients remained asymptomatic and were 
left in situ.
There was one mortality in this series 
in a patient with ARPKD. The remaining 
7 patients were dialysis free, with excellent 
quality of life subjectively, and a mean follow-
up of 2.17 years. The mortality was related 
to surgical complications of hepatic artery 
and portal vein thrombosis peri-operatively. 
Although the patient was re-listed, a second 
liver did not become available and the 
patient died of acute hepatic failure. In the 
patient who received the two kidneys as an 
en bloc graft from a 2-year-old donor, one 
kidney infarcted secondary to renal artery 
thrombosis, although this had no impact on 
renal function. Another patient developed 
a wound haematoma, which resolved with 
conservative management. The last patient, 
who received a reduced left lateral segment 
graft and single kidney, developed abdominal 
compartment syndrome that required urgent 
decompression and closure with a large mesh.
Three of the patients presented with 
mild episodes of rejection. The first had 
a biochemically diagnosed episode of mild 
liver rejection on day 15 post transplant. 
This was successfully managed with 3 doses 
of methylprednisolone without biopsy. The 
second patient presented with a histologically 
confirmed episode of liver rejection two 
years post transplant. This also settled 
completely after increasing the tacrolimus 
dose and adding methylprednisolone. The 
third patient, with aHUS, was transferred 
to another centre for long-term follow-up. 
Presenting with a clinically suggestive episode 
of mild liver rejection, despite a normal liver 
biopsy, the patient was successfully treated 
with methylprednisolone and increased dose 
of tacrolimus. Currently all 7 patients have 
excellent hepatic and renal function. We could 
not conclusively define any documentable 
immunological protection to the renal graft 
in this small patient cohort.
Technical details of the CLKT
The specific surgical techniques for organ 
procurement, graft preparation and the 
respective implant procedures are well 
described. All kidneys were placed extra-
peritoneally via a right-sided Rutherford-
Morrison incision. We did not encounter 
the theoretical risk of skin bridge necrosis at 
the lateral aspects of the right subcostal and 
Rutherford-Morrison incisions where the two 
approximate. The right-sided approach allows 
excellent access to the distal aorta and inferior 
vena cava, which may be required to establish 
adequate arterial inflow and venous outflow, 
respectively. This is especially important 
when a large donor kidney is implanted into 
a small child (weighing <20 kg), when up to 
30% of the circulating blood volume is taken 
up by the transplanted kidney on release 
of clamps. Inadequate arterial inflow will 
compromise perfusion, causing subsequent 
necrosis of the graft. In this situation arterial 
inflow to the donor kidney is established 
directly off the aorta, below the origin of the 
inferior mesenteric artery. This approach was 
utilised in 3/8 renal grafts.
Discussion
All published paediatric CLKTs extracted 
from the PubMed database are shown in 
Table  2. While these total 101 cases,  3  568 
cases have been reported from 1984 to the 
present. The United Network for Organ 
Sharing (UNOS), however, reports that 231 
CKLTs have been performed in children in 
41 transplant centres.[5] The median number 
of transplants per centre was 3 (average 6). 
The majority of transplants were for PH1 
(n=52, 48.6%), ARPKD (n=20, 18.5%) and 
atypical factor H deficiency (n=8, 7.4%). 
Immunosuppression varied significantly from 
tacrolimus or cyclosporin A monotherapy 
to multiple drug combinations and even 
quadruple therapy with antithymoglobulin, 
cyclosporin  A, methylprednisolone and 
azathioprine. When reported, complications 
were predominantly sepsis related (n=6, 
5.94%), and invariably resulted in mortality. 
The relative infrequency of CLKT in children 
is as a result of limited indications, which 
include rare conditions with low incidences 
that have not changed over the years.[2] This 
leaves a challenging problem in determining 
the optimal indications for CLKT. The 
indications for CLKT in our patient cohort 
are listed in Table 1. It is evident, even with the 
small numbers that we are reporting on, that 
our indications and numbers mirror those 
of the world literature. We will discuss the 
three most common indications for CLKT, 
namely PH1, ARPKD with congenital hepatic 
fibrosis and heterozygous factor H deficiency 
with aHUS.
PH1 is an autosomal recessive metabolic 
condition caused by a congenital deficiency 
Table 1. Indications for CLKT in children
Indication Our cohort, n Literature, n
PH1 4 49
PKD 3 17*
Factor H deficiency 1† 7
Methylmalonic acidaemia 7
α1-antitrypsin deficiency 4
Cyclosporin toxicity 2
Failed prior liver transplant 2
Cystinosis 1
Drug toxicity 1
Glycogen storage disease 1a 1
Auto-immune hepatitis/hepatorenal syndrome 1
Sclerosing cholangitis/interstitial nephritis 1
Biliary atresia 1
Liver disease secondary to parenteral nutrition 1
CLKT = combined liver-kidney transplantation; PH1 = primary hyperoxaluria type 1; PKD = polycystic kidney disease.
*Polycystic kidney disease/congenital hepatic fibrosis.
†Heterozygous factor H deficiency with atypical haemolytic uraemic syndrome.
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of alanine-glyoxylate aminotransferase (AGT), a hepatic peroxisomal 
enzyme. Patients with this deficiency metabolise glyoxylate to oxalate 
and glycolic acid instead of glycine.[6] The kidneys are subsequently 
burdened with eliminating the large oxalate load, which results in 
deposition of calcium-oxalate crystals in the kidney and progression 
to chronic renal failure. The condition is often more severe in infants, 
with end-stage renal disease (ESRD) presenting before 2 years of age. 
By 15 years of age 50% of patients will have developed ESRD.[1,3,7] As 
the glomerular filtration rate declines, oxalate is deposited systemically 
into bone and soft tissues including the retina, blood vessels, nerves 
and heart.[6] If the condition is diagnosed early, and before significant 
renal failure is established, isolated liver transplantation (iLT) is 
an acceptable option, with excellent survival.[7] However, this only 
addresses the issue of oxalate formation and does not resolve the 
problem of an already high burden of oxalate, which would force 
the kidneys to eliminate the remaining stores. This can contribute 
to progressive CKD requiring a renal transplant at a later stage. The 
converse is, however, not acceptable – graft survival after isolated 
kidney transplantation (iKT) for PH1 approximates 18% at 3 years, 
based on data from the European Dialysis and Transplant Association 
Table 2. Reported CLKT in children
Author (year)
CLKT, 
n Indication
Age at 
transplant 
(years), mean
Patient 
survival, 
%
Death censored 
renal allograft 
survival, %
Patients with 
rejection, %
Morbidity/mortalityKidney Liver
Polinsky et al.[24] (1991) 1 PH1 7.5 0 NR NR NR Early postoperative 
death*
van ’t Hoff et al.[25] (1998) 1 MMA 13.5 100 100 0 0
Grewal et al.[20] (2000) 12 PKD/CHF (n=5)
α1-antitrypsin 
deficiency (n=2)
Failed prior liver/
cyclosporin toxicity 
(n=2)
Other (n=3)
9.5 67 100 (4.8 years) 42 42 Death due to sepsis post 
transplant (n=4)
Ellis et al.[6] (2001) 4 PH1 7.3 75 100 33 0 Death post transplant 
(n=1)*
Shapiro et al.[7] (2001) 9 PH1 8.5 78 100 (2.5 years) NR NR Death due to sepsis 
(n=1)/PTLD (n=1)
Rogers et al.[21] (2001) 8 PH1 (n=3)
PKD/CHF (n=3)
Cystinosis (n=1)
Drug toxicity (n=1)
10.9 75 50 25 13 Death due to 
pneumonia (n=1)/PTLD 
(n=1)
Gagnadoux et al.[26] (2001) 8 PH1 16.4 75 100 (5 years) 12.5 12.5 Death during transplant 
(n=2)*
Loreno et al.[27] (2002) 1 α1-antitrypsin 
deficiency
15 100 100 0 100
Remuzzi et al.[17] (2005) 1 Factor H deficiency 2 100 100 NR 100 Re-transplanted liver at 
1 month
Millan et al.[28] (2003) 6 PH1 1.2 100 100 (6.4 years) 16.70 67
Nagarajan et al.[29] (2005) 2 MMA 15.5 100 100 NR NR
Herden et al.[1] (2011) 14 PH1 (n=7)
PKD/CHF (n=7)
8 100 93 NR NR Primary non-function 
of the liver graft and 
impaired kidney 
function requiring 
re-CLKT (two livers)
One re-liver transplant 
for outflow problem 
with toxic liver damage
Khan et al.[15] (2002) 1 Factor H deficiency 3 100 100 100 100 Delayed renal graft 
function
Sakamoto et al.[30] (2012) 1 Caroli’s disease/
ARPKD
4.3 0 NR NR NR Death (n=1)
CLKT = combined liver-kidney transplantation; NR = not reported; PH1 = primary hyperoxaluria type 1; MMA = methylmalonic acidaemia; PKD = polycystic kidney disease;  
CHF = congenital hepatic fibrosis; MMA, methylmalonic acidaemia; PTLD = post-transplant lymphoproliferative disorder; ARPKD = autosomal recessive polycystic kidney disease.
*Cause not specified.
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registry.[8] This obviously occurs due to progressive nephrocalcinosis 
and urolithiasis and early graft failure, as hepatic AGT is still deficient, 
and oxalate over-production continues.
CLKT addresses both the primary metabolic insult, namely 
hepatic AGT deficiency, and the consequent end-organ damage 
secondary to oxalosis, i.e. chronic renal failure. Reported outcomes 
have been varied. The largest series of patients is from the European 
PH1 Transplant Registry; 127 transplants were performed in 117 
patients between 1984 and 2005, 99 CLKTs, 22 iLTs and 6 patients 
underwent iLT followed by iKT. The 10-year survival was 69% for 
all groups.[9] Factors which were clearly shown to affect outcome and 
improve survival were the overall clinical condition of the patient 
at the time of transplantation, earlier diagnosis and aggressive pre-
transplantation dialysis.[1,2,4,9] Of interest is that, despite a new liver, 
>50% of renal graft failures following CLKT were due to oxalate 
deposition in the new kidney and that hyperoxaluria was detectable 
up to 45 months post transplantation. This oxalate burden should 
not be underestimated.[2,10] One of our patients required both haemo- 
and peritoneal dialysis preoperatively. Our current protocol is to 
perform haemodialysis 4 - 5 times per week pre-transplant and for 
3 months post transplantation to decrease the oxalate load and to 
mitigate any damage to the renal allograft by nephrocalcinosis or 
urolithiasis. Consideration should also be given to the shortage of 
deceased donor organs and the resulting pressure to other patients 
on the waiting list. Thus, alternatives that should be considered once 
the decision to list has been taken include the feasibility of related 
living kidney donation as and when a deceased donor liver becomes 
available, as well as consideration of both related living kidney and 
liver transplantation simultaneously.[1,11] 
ARPKD has an incidence of 1/20 000 live births and demonstrates 
a variable clinical progression.[2,12] The most severely affected children 
present with ESRD, either in the perinatal period or during early 
infancy. Liver involvement is a result of congenital hepatic fibrosis 
or Caroli disease, which may progress to portal hypertension, 
hypersplenism with resultant thrombocytopenia and recurrent 
ascending cholangitis (Caroli syndrome).[6,13] As the liver disease is 
chronic and may not necessarily progress to failure, iKT has been the 
standard intervention for ESRD secondary to ARPKD with minimal 
liver disease. Reported data on iKT show patient survival to be 89% 
and death censored graft survival at 100% at 5 years.[14] However, 
Khan et al.[15] reported on 14 patients who had received iKT in the 
presence of hepatic disease; 4/5 deaths in this series were due to 
complications from hepatic disease (systemic sepsis secondary to 
cholangitis) and 56% of the remaining survivors had complications 
related to congenital hepatic fibrosis at a mean of 6.3 years post 
transplantation. Davis et al.[13] published a retrospective study of 
203 patients who received iKT for similar indications. Of particular 
interest in this study is the 64% of sepsis-related deaths. While sepsis 
is acknowledged as a common cause of death among the paediatric 
group of kidney transplant recipients, the North American Pediatric 
Renal Trials and Collaborative Studies registry report this at 
28.9%. [6,16] Although not proven, this may hypothetically suggest an 
increased rate of cholangitis related to congenital hepatic fibrosis, 
and the fact that these patients already have a heavily colonised 
biliary tree. This situation is possibly accentuated by subsequent 
immunosuppression.[7,13] While liver disease is always present in 
these patients, it does not always warrant transplantation and iKT 
is often all that is required. When there is liver disease causing 
progressive and severe complications, CLKT is advocated. Although 
limited, outcome data following both adult and paediatric CLKT 
are favourable in the literature. CLKT should be considered when 
ESRD (as a result of ARPKD) and severe congenital hepatic fibrosis 
or hepatic failure are present. On occasion, liver disease secondary 
to the congenital hepatic fibrosis dominates the clinical picture. 
However, we are not aware of any cases of iLT in the literature and 
CLKT is recommended currently in this scenario.[8,11] 
Heterozygous factor H deficiency with aHUS is a very unusual 
indication for CLKT, with only 7 cases described in the literature to 
date. Factor H is produced in the liver and regulates the activation 
of the complement cascade via the alternative pathway. Qualitative 
or quantitative deficiencies in factor H can result in the uninhibited 
deposition of complement, destruction of microvasculature and 
phenotype of HUS. There are >60 heterozygous factor H mutations 
that are responsible for ~30% of recurrent cases of HUS. They carry 
a poor prognosis, resulting in ESRD or death in 50% of patients. [3,9,17,18] 
Outcomes following iKT are equally poor, with recurrences in the 
range of 50 - 100%.[3,17] CLKT addresses both the qualitative and 
quantitative factor H issues and restores renal function. Recently, 
eculizumab has been registered for the management of aHUS. 
Eculizumab is a recombinant, humanised monoclonal antibody 
targeting the complement protein C5. It protects red blood cells from 
chronic intravascular haemolysis by preventing generation of the C5b9 
complex, thus inhibiting activation of terminal complement, which is 
responsible for cell lysis. The current recommendation is to perform 
a kidney transplant combined with lifelong eculizumab therapy.[19] 
Unfortunately, the lifelong cost of this drug is currently prohibitively 
high. The alternative is CLKT, which is a more aggressive treatment 
option and is potentially associated with greater morbidity and 
mortality due to the combined organ transplant. To reduce this risk, 
an option is to use one dose of eculizumab peri-operatively in CLKTs 
to reduce the complications related to uninhibited complement 
activation. A second dose can be held in reserve if necessary. Where 
antifactor H antibodies exist a CKLT may need to be combined with 
lifelong plasma exchange and therapy aimed at reducing antibody 
levels. Our patient did not have antifactor H antibodies.
At the time of writing, CLKT has been reported in 7 patients 
(including our own case) with factor H-associated HUS. Most 
recently, Khan et al.[15] reported one case that was uncomplicated, 
apart from a short period of delayed renal graft function of the 
kidney. Saland et al.[3] also published a single case with 100% dual 
graft survival at 2 years. Our case was equally uncomplicated, 
with dual graft survival >2 years post transplant. Plasma exchange 
has been suggested in the immediate pre-transplant period, or 
intraoperatively, as it restores normal factor H function and inhibits 
unregulated complement deposition until the new liver has had 
time to normalise factor H levels and function. Also, because split 
liver grafts are more susceptible to poor perfusion and the resultant 
increased complement activation, it is suggested by some units that 
whole liver grafts be used.[18] It should be stated that this is not the 
practice of our unit and we would consider the use of split grafts 
without reservation. Although there are only a limited number of 
documented cases in addition to our own single case experience, 
it has been demonstrated that, in light of these recent successes, as 
well as the poor outcomes of alternative therapy, CLKT should be 
considered for this subgroup of patients.
Since CLKTs are now more commonly performed, there has been 
debate as to whether the liver allograft offers ‘immunoprotection’ 
to the kidney allograft. In 2003, a review of the UNOS database 
illustrated a lower 6-month cumulative acute renal rejection rate for 
patients receiving CLKT than iKT (21.5% v. 30.1%, respectively). 
When reviewing single-centre experiences, the results appear even 
more promising; however, the small numbers reported in these 
studies should caution their interpretation. Grewal et al.[20] reported a 
42% acute renal allograft rejection rate but only 2/5 cases were proven 
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by biopsy. Rogers et al.[21] showed a 25% acute renal allograft rejection 
rate v. a 86% rejection rate in the kidney after liver transplant 
cohort. More recently, de la Cerda et al.[22] conducted a single-
centre, retrospective, case-control study that looked at 10 children 
who had CLKT and survived to 6 months, comparing them to a 
control group of 20 kidney-only transplants matched for age, era and 
immunosuppression. In the CLKT group, only 1 acute renal allograft 
rejection was reported at 7 years secondary to non-compliance of 
medication. In the same period, the kidney-only group had 16 acute 
rejection episodes. There was also no hepatic rejection in the CLKT 
group. The study was, however, too small to uncover a significant 
difference in immunologically mediated kidney allograft failure. The 
same authors therefore looked at UNOS paediatric data, analysing 
111 CLKT and 3  798 kidney-only transplants between 1995 and 
2005. They found that, although renal graft loss in the first 6 months 
was higher in the CLKT than the kidney-only group (20.1% v. 5.9%, 
respectively), death-censored kidney allograft survival at 5 years was 
significantly better in the CLKT group and that function did not 
continue to deteriorate as it did in the kidney-only group.[22] 
When reviewing the literature there are a few reported cases 
where patients required re-liver transplant after CLKT for graft 
non-function or rejection. In one case, a patient received two 
subsequent liver transplants following the initial CLKT.[23] Although 
that patient did not ultimately survive, the feasibility of subsequent 
transplantation does exist, dependent obviously on the availability 
of organs. This does validate our suggestion that our single mortality 
might have survived had another organ been available and, at the 
same time, raises the question of utilising a scarce resource.
Conclusion
Our centre demonstrates equivalent results in terms of graft 
survival, morbidity and mortality compared with reported data in 
the international literature. In the paediatric age group, the most 
common indications for CLKT are metabolic diseases, which affect 
either the kidney alone with or without liver dysfunction or disorders 
affecting both organs simultaneously. CLKT has good results in select 
groups of patients and long-term survival approaches that of liver 
transplantation alone. Outcomes are optimised by early evaluation 
and listing, before patients manifest systemic complications and 
develop end-stage disease. It is our strong view that all options 
should be utilised in transplanting these patients, including deceased 
donor split livers, RLD kidneys with deceased donor liver, and 
the RLD option for both liver and kidney. In patients with PH1, 
nephrocalcinosis and systemic oxalosis can be problematic post 
transplant and 3 months dialysis post CLKT to clear systemic oxalic 
acid is recommended. Irreversible renal dysfunction should not 
exclude children with severe liver disease from consideration for 
liver transplantation if it is performed with a simultaneous kidney 
transplant. Factors that negatively affect the outcome of iLT (UNOS 
status and re-transplantation) must be considered in determining the 
suitability of any given candidate for CLKT but ultimately ESRD and 
poor quality of life need to be offset against the potential excellent 
long-term benefits of a timeous CLKT. Similarly, patients with 
ARPKD demonstrate excellent graft and patient survival. Regarding 
mortality occurring in ARPKD, 64 - 80% can be attributed to systemic 
sepsis, likely a consequence of cholangitis subsequent to their liver 
disease. As surgical mortality in paediatric liver transplant recipients 
has been shown to be <10% at one year, CLKT is a viable option to 
decrease overall mortality in patients with recurrent cholangitis or 
complications of portal hypertension. There is suggestive clinical 
evidence that CLKT offers a degree of immunological protection to 
the renal allograft.
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